ReviewCancers2022
Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 499 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
499 citing papers in PubMed, 6 syntheses or guidelines pooled it, 810 citations in OpenAlex.
- Therapeutic effects of silibinin in preclinical animal models of gastrointestinal cancers: a systematic review and meta‑analysis.BMC cancer · 2026Pooled it
- Deep learning driven colorectal polyp analysis: a review of detection, classification and segmentation methods.Frontiers in artificial intelligence · 2026Pooled it
- Pooled it
- Dietary inflammatory index and the risk of colorectal adenomas and cancer: a systematic review and dose-response meta-analysis.Nutrition journal · 2025Pooled it
- Association between red and processed meat consumption and colorectal cancer risk: a comprehensive meta-analysis of prospective studies.GeroScience · 2025Pooled it
- Clinical Prediction Models for Contact X-Ray Brachytherapy in Managing Rectal Cancers: A Scoping Review.Cancer medicine · 2025Pooled it
- Amivantamab Monotherapy in ChemorefractoryJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Application of the behavior change wheel in supporting self-management among colorectal cancer survivors: A scoping review.Asia-Pacific journal of oncology nursing · 2026Review
- Integrating multi-modal biological knowledge via contrastive dual-view graph learning for phosphorylation site-disease association prediction.Bioinformatics (Oxford, England) · 2026Article
- A Hybrid Lightweight Deep Learning Framework for Colorectal Cancer Detection Using an Adaptive Gated Feature Fusion and Grid Search-Based Hyperparameter Optimization.Journal of imaging informatics in medicine · 2026Article
- Silymarin and Zinc Oxide Nanoparticles Attenuate Experimental Colon Cancer in Rats Through Crosstalk of miR-192 and β-Catenin Pathways.Biomolecules · 2026Article
- Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies.International journal of molecular sciences · 2026Review
- Fourier-based chemometric resolution of the FOLFOX regimen through digital filtering with poly-metric sustainability assessment.Scientific reports · 2026Article
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- Article
- Urinary Volatilomic Profiling Reveals Candidate Metabolomic Signatures Associated with Colorectal Cancer.Biology · 2026Article
- Non-invasive colorectal cancer screening: emerging tools and clinical evidence.Clinical endoscopy · 2026Review
- Unveiling the potential of solid lipid nanoparticles of apigenin-Cu(II) coordinated nanocomplex in colon cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Telmisartan Repurposing Targets Novel Biomarkers for Precision Colorectal Cancer Therapy.Pharmaceutics · 2026Article
439 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the second most deadly cancer. Global incidence and mortality are likely to be increased in the coming decades. Although the deaths associated with CRC are very high in high-income countries, the incidence and fatalities related to CRC are growing in developing countries too. CRC detected early is entirely curable by surgery and subsequent medications. However, the recurrence rate is high, and cancer drug resistance increases the treatment failure rate. Access to early diagnosis and treatment of CRC for survival is somewhat possible in developed countries. However, these facilities are rarely available in developing countries. Highlighting the current status of CRC, its development, risk factors, and management is crucial in creating public awareness. Therefore, in this review, we have comprehensively discussed the current global epidemiology, drug resistance, challenges, risk factors, and preventive and treatment strategies of CRC. Additionally, there is a brief discussion on the CRC development pathways and recommendations for preventing and treating CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.